AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
Phase 3
Completed
- Conditions
- Non-erosive Reflux Disease
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 270
- Registration Number
- NCT00259077
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
Phase 3
Completed
- Conditions
- Non-erosive Reflux Disease
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00259051
- Locations
- 🇯🇵
Research Site, Yamato, Japan
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00259090
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Iressa v BSC (Best Supportive Care) in First Line NSCLC
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 216
- Registration Number
- NCT00259064
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 655
- Registration Number
- NCT00257205
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Sopran - Omeprazole Treatment Versus Surgery
Phase 3
Completed
- Conditions
- GERD
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 219
- Registration Number
- NCT00256737
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
Phase II Iressa Versus Vinorelbine (INVITE)
Phase 2
Completed
- Conditions
- Non-Small-Cell Lung Carcinoma
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT00256711
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00256698
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small-cell Lung Cancer
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00255489
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00255502
- Locations
- 🇩🇴
Research Site, Santa Domingo, Dominican Republic
© Copyright 2025. All Rights Reserved by MedPath